GABA
Also known as: Gamma-aminobutyric acid, γ-aminobutyric acid
Randomized trials in humans provide mixed but promising findings for oral GABA on sleep quality, emotional measures (anxiety/depression/stress) and symptom scores in IBS‑D when given for weeks to months. Effects have been observed when GABA was given alone (e.g. 200 mg/day for 90 days) or combined with other agents (e.g. 50 mg GABA plus EstroG‑100). A pediatric trial in new‑onset type 1 diabetes found no preservation of insulin secretion. Some trials are small or pilot in design, and formulations/doses vary.
Last reviewed: 2026-10-14 · 4 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
GABA (gamma‑aminobutyric acid) is an inhibitory neurotransmitter commonly used as an oral supplement for sleep, stress and mood support. Clinical trials have tested oral GABA alone or in combination with other ingredients for a range of outcomes including sleep quality, anxiety/depression scores and irritable bowel symptoms.
Mechanism & Function
Mechanism of Action
GABA is the main inhibitory neurotransmitter in the central nervous system; orally administered GABA is proposed to influence autonomic balance and central inhibitory tone and may reduce visceral hypersensitivity and systemic inflammation in specific conditions according to the clinical trials reported.
Physiological Role
Neurotransmission via GABAA/GABAB receptors; modulation of autonomic nervous system balance; putative effects on visceral sensitivity and inflammatory mediators in gut disorders.
Primary Pathways
Performance / Health Relevance
May modestly improve sleep efficiency and emotional state which can indirectly affect recovery and overall wellbeing; evidence for direct ergogenic benefits is lacking in the provided trials.
Evidence Review
No meta-analyses or systematic reviews indexed for this ingredient yet.
Dimensions marked N/A have no indexed evidence of that class. They are shown as unavailable rather than scored.
Practical Use & Dosage
- Minimum Effective Dose
- 50 mg/day (reported in combination product) or 200 mg/day (reported as single‑ingredient in one trial)
- Optimal Range
- Not established due to heterogeneity of trials and formulations
- Upper / Caution Level
- Not established
- Timing
- Varied by study; daily dosing in most trials, one study allowed PRN use for vasomotor symptoms during an initial phase
- Best Format
- Oral capsules/tablets as used in clinical trials
- Bioavailability
- Oral bioavailability and CNS penetration are variable and not established from these abstracts
- Absorption Considerations
- Not reported in the provided abstracts
Safety & Interactions
Side Effects
- •No major safety signals reported in the provided trials
- •Tolerability reported as acceptable in the pediatric T1D trial
Contraindications
- Not specified in the provided abstracts
Drug Interactions
- •Not reported in the provided abstracts
Who Should Avoid
- •Not specified in the provided abstracts; exercise caution in clinical populations until larger trials are available
Monitoring
Monitor symptom response and tolerability; larger safety datasets not available from the provided abstracts
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is GABA typically used or indicated?
GABA is most commonly used for: Sleep support, Stress and anxiety relief, Mood support, Irritable bowel symptom management. Neurotransmission via GABAA/GABAB receptors; modulation of autonomic nervous system balance; putative effects on visceral sensitivity and inflammatory mediators in gut disorders.
How does GABA work?
GABA is the main inhibitory neurotransmitter in the central nervous system; orally administered GABA is proposed to influence autonomic balance and central inhibitory tone and may reduce visceral hypersensitivity and systemic inflammation in specific conditions according to the clinical trials reported.
What is the recommended dose of GABA?
The optimal range is Not established due to heterogeneity of trials and formulations. with a minimum effective dose of 50 mg/day (reported in combination product) or 200 mg/day (reported as single‑ingredient in one trial). Best taken: Varied by study; daily dosing in most trials, one study allowed PRN use for vasomotor symptoms during an initial phase. Upper / caution level: Not established.
What are the side effects of GABA?
Reported side effects include: No major safety signals reported in the provided trials; and Tolerability reported as acceptable in the pediatric T1D trial. Monitoring: Monitor symptom response and tolerability; larger safety datasets not available from the provided abstracts
Does GABA interact with medications?
Known or theoretical interactions: Not reported in the provided abstracts. Always check with a clinician before combining with prescription medication.
Who should avoid GABA?
GABA is generally not recommended for: Not specified in the provided abstracts; exercise caution in clinical populations until larger trials are available; and Not specified in the provided abstracts.
How strong is the evidence for GABA?
Evidence level: Moderate (overall score 63/100), based on 4 indexed studies on SuppIndex.
Research & References (4)
Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study.
Randomized double‑blind placebo‑controlled study of a nutraceutical combining EstroG‑100 (514 mg) with GABA (50 mg) versus placebo in 80 menopausal women, with an initial PRN phase followed by daily dosing for weeks 2–5.
GABA Supplementation, Increased Heart-Rate Variability, Emotional Response, Sleep Efficiency and Reduced Depression in Sedentary Overweight Women Undergoing Physical Exercise: Placebo-Controlled, Randomized Clinical Trial.
Placebo‑controlled randomized trial in 30 sedentary overweight women undergoing exercise, testing oral GABA 200 mg once daily versus placebo for 90 days.
Effects of γ-Aminobutyric Acid (GABA) Supplementation on Symptoms, Quality of Life, Intestinal Permeability, Systemic Inflammation and Gut Microbiota in Patients with IBS-D: A Randomized, Double Blind, Placebo-Controlled, Crossover Pilot Study.
Randomized double‑blind placebo‑controlled crossover pilot study in 20 IBS‑D patients testing a GABA‑based supplement versus placebo for two 4‑week periods separated by a 2‑week washout.
A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes.
Single‑centre double‑blind randomized one‑year trial in 97 children with new‑onset type 1 diabetes comparing oral GABA twice daily, GABA plus GAD‑alum, and placebo.
Related Ingredients
Other top-rated ingredients in Amino Acids.
L-Leucine
82/100Essential BCAA that activates mTORC1 via Sestrin2 sensing, driving phosphorylation of S6K1 and 4E-BP1, initiating cap-dependent translation and muscle protein synthesis.
Beta-Alanine
78/100A rate-limiting precursor to carnosine (β-alanyl-L-histidine) synthesis, enhancing intramuscular pH buffering capacity during high-intensity anaerobic exercise.
EAA Blend
78/100Free-form blend of 9 EAAs (Leu, Ile, Val, Lys, Met, Phe, Thr, Trp, His) at evidence-based ratios; bypasses gastric digestion for rapid plasma aminoacidaemia.
Research Overview
Moderate EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/gaba
SuppIndex. (2026). GABA: Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/gaba
Based on 4 indexed studies · Evidence level: Moderate.
Goal Ratings
Stack Compatibility
Often studied in combination with other nutraceuticals (e.g. EstroG‑100) or enzymes; interactions not characterised in these abstracts